No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma

Atsushi Kumagai, Hiroyuki Namba, Takakura Shu, Eiko Inamasu, Vladimir A. Saenko, Akira Ohtsuru, Shunichi Yamashita

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The MAPK signaling pathway plays a crucial role in tumorgenesis and cell proliferation in human papillary thyroid carcinoma (PTC). Ret/PTC rearrangements, RAS and BRAF mutations, the main non-overlapping genetic alterations all leading to MAPK cascade activation, are cumulatively identified in 60-80% of PTCs. In approximately one-fourth of the cases, oncogenic background potentially contributing to MAPK activation in PTC might be different. We therefore attempted to evaluate the mutational status of genes encoding other members of RAF family known to act upstream of MAPKs, ARAF and CRAF (RAF-1). In addition we also analyzed the MET gene that encodes hepatocyte growth factor/scatter factor receptor overexpressed in most of PTCs and a MAPK cascade contributor. In 129 Japanese patients with PTC, BRAFT1799A was detected in 65 cases (50.4%), and the remaining 64 tumor specimens were subjected to mutation analysis of kinase domains of ARAF, CRAF and MET genes, and hotspots of K- and N-RAS genes. No ARAF, CRAF, MET, K- and N-RAS mutations were revealed. Based on these observations, we concluded that despite the fact that ARAF, CRAF and MET are actively expressed, alterations of these genes are rare in PTC and unlikely to play a perceptible role in the molecular pathogenesis of this type of human malignancy.

Original languageEnglish
Pages (from-to)615-620
Number of pages6
JournalEndocrine Journal
Volume53
Issue number5
DOIs
Publication statusPublished - 2006
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'No evidence of ARAF, CRAF and MET mutations in BRAF<sup>T1799A</sup> negative human papillary thyroid carcinoma'. Together they form a unique fingerprint.

Cite this